SMO and small cell lung carcinoma: Despite these promising results, a large phase II trial combining the SMO antagonist, vismodegib, with etoposide and cisplatin concurrently and then as maintenance therapy to treat extensive stage SCLC patients in the first line setting showed no overall- or progression-free survival benefit over cisplatin and etoposide alone [192].